[go: up one dir, main page]

Barbaro et al., 2000 - Google Patents

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience

Barbaro et al., 2000

View PDF
Document ID
14338106593558021094
Author
Barbaro G
Di Lorenzo G
Soldini M
Giancaspro G
Pellicelli A
Grisorio B
Barbarini G
Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators
et al.
Publication year
Publication venue
Journal of hepatology

External Links

Snippet

Background/Aims: A combination of interferon alpha and ribavirin has been suggested to reach a higher rate of sustained virological response in patients with chronic hepatitis C than monotherapy. In this study we assessed the long-term efficacy of this combination therapy in …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Barbaro et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial
Barbaro et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
Ikeda et al. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life
Lee et al. Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
Lindsay et al. Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: a randomized multicenter trial
Rossum et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double‐blind, randomized, placebo‐controlled phase I/II trial
Barbaro et al. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience
Landau et al. Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
Bodenheimer Jr et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial
Madejón et al. Treatment of chronic hepatitis D virus infection with low and high doses of interferon‐α2a: utility of polymerase chain reaction in monitoring antiviral response
Arif et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin
Zoulim et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients
Barbaro et al. Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: an Italian multicenter, randomized, controlled, clinical study
Hiramatsu et al. Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin
Andreone et al. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: results of a randomized multicenter trial
Lee et al. The natural history and antiviral treatment of hepatitis C in haemophilia
Lam Hepatitis C: natural history, diagnosis, and management
Mazzaro et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis
Ruiz-Moreno et al. Levamisole and interferon in children with chronic hepatitis B
Narkewicz et al. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment
Barbaro et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha
Kagawa et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C
Carlsson et al. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin
Cozzolongo et al. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon
De Paoli Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects